美国全球 Rozanolixizumab（Rystiggo）市场：市场规模、份额、趋势分析（按适应症和分销管道）、细分市场预测（2025-2033）

美国Rozanolixizumab（Rystiggo）市场概况

美国Rozanolixizumab (Rystiggo) 市场规模预计在2024年达到1.9913亿美元，预计2025年至2033年的复合年增长率为7.30%。美国Rozanolixizumab (Rystiggo) 市场专注于治疗携带抗乙酰胆碱受体 (AChR) 或抗麝香 (MuSK) 抗体的成人重症全身性重症肌无力 (gMG)。在美国医疗基础设施和报销政策的支持下，对生物目标的需求正在推动市场成长。

美国FDA于2023年6月核准rozanolixizumab (Rystiggo)用于治疗鉅细胞性肌无力(gMG)，将推动美国市场的成长。鉅细胞性肌无力(gMG)的诊断数量不断增长（估计每10万美国成年人中有3.2人确诊），以及针对自体免疫疾病的生物製药需求的不断增长，共同推动着市场的增长。 UCB製药专注于皮下给药，这提高了患者的便利性，并支持了市场的扩张。预计到2033年，该市场规模将达到7.3298亿美元，复合年增长率高达7.30%。

Rozanolixizumab (Rystiggo) 因其作用机製而脱颖而出，即透过抑制 FcRn 来降低 IgG 水平，与传统免疫抑制剂相比，它提供了一种新颖的治疗方法。核准用于抗乙酰胆碱受体 (AChR) 和抗麝香 (MuSK) 抗体阳性患者，扩大了其市场覆盖范围。其竞争优势包括副作用更少、给药方式灵活，使其在与依加替莫德 (efgartigimod) 等替代药物的竞争中占据优势。优时比 (UCB) 的行销工作重点突出了这些优势，目标客户是神经科和专科诊所。

新兴创新包括针对慢性脱髓鞘多发性神经炎(CIDP) 等其他适应症的试验，这可能会扩大 gMG 以外的市场。美国凭藉其研究基础设施处于领先地位，2024 年的临床试验数据表明，到 2027 年，该药物将得到更广泛的应用。透过专科药局和电商平台加强分销，顺应病患可及性趋势，将进一步支持成长。

目录

第一章 分析方法与范围

第二章执行摘要

第三章美国Rozanolixizumab（Rystiggo）市场：驱动因素、趋势与范围

• 市场联动展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制分析
• 商业环境分析
  • 产业分析：波特五力分析
  • PESTEL分析
  • 管道分析
  • 专利到期分析
  • 定价分析

第四章美国Rozanolixizumab（Rystiggo）市场：按适应症进行的商业分析

• 各适应症市场占有率（2024 年及 2033 年）
• 细分仪表板：依指示
• 市场规模预测及趋势分析（2021-2033）
• 全身性重症肌无力（gMG）
• 新的管道应用

第五章美国Rozanolixizumab（Rystiggo）市场：按通路进行的业务分析

• 按分销管道分類的市场占有率（2024 年和 2033 年）
• 细分仪表板：按分销管道
• 按分销管道分類的市场规模预测和趋势分析（2021-2033 年）
• 医院和专科药房
• 零售与电子商务

第六章 竞争态势

• 参与企业概况
• 企业市场分析
• 公司分类
• 战略地图
• 公司简介/上市公司
  • UCB

U.S. Rozanolixizumab (Rystiggo) Market Summary

The U.S. Rozanolixizumab (Rystiggo) market size was estimated at USD 199.13 million in 2024 and is expected to grow at a CAGR of 7.30% from 2025 to 2033. The U.S. Rozanolixizumab (Rystiggo) market focuses on treating generalized myasthenia gravis (gMG) in adults with anti-AChR or anti-MuSK antibodies. Growth is driven by demand for targeted biologics, supported by U.S. healthcare infrastructure and reimbursement policies.

The U.S. Rozanolixizumab (Rystiggo) market benefits from the drug's FDA approval in June 2023 for gMG treatment. Growth is propelled by rising gMG diagnoses, estimated at 3.2 per 100,000 U.S. adults for the MG cases, and increasing demand for biologics targeting autoimmune disorders. UCB Pharma's focus on subcutaneous administration enhances patient convenience, supporting market expansion. Projections to USD 732.98 million by 3033 reflect a steady CAGR of 7.30%, driven by ongoing clinical advancements and healthcare investments.

Rozanolixizumab (Rystiggo) stands out due to its mechanism of action, reducing IgG levels via FcRn inhibition, offering a novel approach compared to traditional immunosuppressants. Its approval for both anti-AChR and anti-MuSK antibody-positive patients broadens its market scope. Competitive advantages include fewer side effects and flexible dosing, positioning it favorably against alternatives such as efgartigimod. UCB's marketing efforts emphasize these benefits, targeting neurologists and specialty clinics.

Emerging innovations include trials for additional indications, such as chronic inflammatory demyelinating polyneuropathy (CIDP), which could expand the market beyond gMG. The U.S. leads due to its research infrastructure, with clinical trial data from 2024 suggesting broader applications by 2027. Distribution enhancements via specialty pharmacies and e-commerce platforms further support growth, aligning with patient access trends.

U.S. Rozanolixizumab (Rystiggo) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Rozanolixizumab (Rystiggo) market report based on indication and distribution channel:

• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Generalized Myasthenia Gravis (gMG)
• Emerging Pipeline Applications
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital & Specialty Pharmacies
• Retail & E Commerce

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Rozanolixizumab (Rystiggo) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Rozanolixizumab (Rystiggo) Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2033
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 4.4. Generalized Myasthenia Gravis (gMG)
  • 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2021 - 2033 (USD Million)
• 4.5. Emerging Pipeline Applications
  • 4.5.1. Emerging Pipeline Applications Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Rozanolixizumab (Rystiggo) Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2033
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 5.4. Hospital & Specialty Pharmacies
  • 5.4.1. Hospital & Specialty Pharmacies Market, 2021 - 2033 (USD Million)
• 5.5. Retail & E-Commerce
  • 5.5.1. Retail & E-Commerce Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. UCB
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
• Table 4 U.S. Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Rozanolixizumab (Rystiggo) market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 U.S. Rozanolixizumab (Rystiggo) Market dynamics
• Fig. 12 U.S. Rozanolixizumab (Rystiggo) Market: Porter's five forces analysis
• Fig. 13 U.S. Rozanolixizumab (Rystiggo) Market: PESTLE analysis
• Fig. 14 Indication market, 2021 - 2033 (USD Million)
• Fig. 15 Generalized Myasthenia Gravis (gMG) market, 2021 - 2033 (USD Million)
• Fig. 16 Emerging Pipeline Applications market, 2021 - 2033 (USD Million)
• Fig. 17 Distribution Channel market, 2021 - 2033 (USD Million)
• Fig. 18 Hospital & Specialty Pharmacies market, 2021 - 2033 (USD Million)
• Fig. 19 Retail & E-Commerce market, 2021 - 2033 (USD Million)
• Fig. 20 U.S. Rozanolixizumab (Rystiggo) Market revenue, by region
• Fig. 21 Regional marketplace: Key takeaways
• Fig. 22 U.S. country dynamics
• Fig. 23 U.S. Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
• Fig. 24 Company categorization
• Fig. 25 Company market position analysis
• Fig. 26 Strategic framework